Tirzepatide is a gastric inhibitory polypeptide analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss.
Mounjaro (tirzepatide) is the first and only, once-weekly approved single-molecule GIP and GLP-1 receptor agonist that helps lower A1C for adults with type 2 diabetes.
GLP-1 receptor agonists in type 2 diabetes management: Current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 28812892.
Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies-such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations, and high-dose...
Use moderate doses of GLP-1 receptor agonists, rather than pushing to the highest possible dose solely to achieve rapid weight loss.
But you can't get it yet. Eli Lilly's experimental oral GLP-1 receptor agonist demonstrated mean body weight reductions of 14.7% at the highest dose over 36 weeks, nearly matching semaglutide's injectable performance without requiring weekly injections.
Effects GLP-1 RAs. Recent advances in GLP-1 receptor pharmacology have further expanded the therapeutic potential of these agents. Studies investigating their use in higher doses, extended formulations, and as part of dual- or triple-agonist therapies have revealed...
The implant delivers high doses of exenatide, a GLP-1 receptor agonist commercialized by AstraZeneca as Bydureon for treating Type 2 diabetes.
